___

• Abrams P, Cardozo L, Fall M, et al. The standardization
• of terminology of lower urinary tract function: report
• from the Standardization Subcommittee of the
• International Continence Society. Neurourol Urodyn
• : 21: 167-178.
• Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J,
• Wein AJ. How widespread are the symptoms of an
• overactive bladder and how are they managed? A
• population based prevalence study. BJU Int 2001: 87:
• -766.
• Milson I, Stewart W, Thuroff J. The prevalence of
• overactive bladder. Am J Manag Care 6 (Suppl. 11)
• : S565-5573
• Yoshimura N, de Groat WC. Neural control of lower
• urinary tract. Int J Urol 1997: 4: 111-125.
• De Groat WC. A neurologic basis for the overactive
• bladder. Urology suppl. 1997: 50: 36-52.
• Wang P, Luthin GR, Ruggieri MR. Muscarinic
• acetylcholine receptor subtypes mediating urinary
• bladder contractility and coupling to GTP binding
• proteins. J Pharmacol Exp Ther 1995: 273: 959-966.
• Yoshimura N, Chancellor MB. Current and future
• pharmacological treatment for overactive bladder. J Urol
• : 168:1897-1913.
• Wein AJ. Neuromuscular dysfunction of lower urinary
• tract and its management. In: Walsh PC, Retik AB,
• Darracot Vaughan jr. E, Wein AJ (eds) Campell’s
• Urology. Saunders, Philadelphia, 2002: 931-1026.
• Madersbacher H, Rovner E. Trospium chloride: the
• European experience. Expert Opin Pharmacother 2006:
• :1373-1380.
• Hofner K, Oelke M, Machtens S, Grunewald T.
• Trospium chloride an effective drug in the treatment of
• overactive bladder and detrusor hyperreflexia. World J
• Urol 2001: 19: 336-343.
• Guay DR. Clinical pharmacokinetics of drugs used to
• treat urge incontinence. Clin Pharmacokinet 1986: 42:
• -1285.
• Vereecken RL. A critical view on the value of
• urodynamics in non neurogenic incontinence in women.
• Int Urogynecol J 2000: 11: 188-195.
• Coyne KS, Zyczynski T, Margolis MK, Elinof V,
• Roberts RG. Validation of an overactive bladder
• awareness tool for use in primary care settings. Adv
• Ther 2005: 22: 381-394.
• Hu TW, Wagner TH, Bentkover JD, et al. Estimated
• economic cost of overactive bladder in the United
• States. Urology 2003: 61: 1123-1128.
• Abrams P, Anderson KE. Muscarinic receptor
• anragonists for overactive bladder. BTU Int 2007: 100:
• -1006.
• Zinner M, Gittelman M, Haris R, et al. Trospium
• chloride improves bladder symptoms. A multicenter
• phase III trial. J Urol 2004:171: 2311-2315.
• Rudy D, Cline K, Harris R, et al.Multicenter phase III
• trial studying trospium chloride in patients with over
• active bladder. Urology 2006; 67:275-280.
• Halaska M, Ralph G, Wiedeman A, et al. Controlled,
• double-blind, multicenter clinical trial to investigate
• long-term tolerability and efficacy of trospium chloride
• in patients with detrusor instability. World J Urol 2002:
• : 392-399.
• Flisser A, Walmsey K, Blavias JG. Urodynamics
• classification of patients with symptoms of overactive
• bladder. J Urol 2003: 169: 529-533.
• Lin LY, Yeh NH, Lin CY, Sheu BC, Lin HH.
• Comparisons of urodynamic characteristics between
• female patients with overactive bladder and overactive
• bladder plus stress urinary incontinence. Urology 2004:
• : 945-949.
• Digesu GA, Khullar V, Cardozo L, Stefano S.
• Overactive bladder symptoms: Do we need
• urodynamics? Neurourol Urodyn 2003: 22: 105-108.
• Ouslander JG. Management of overactive bladder. N
• Engl J Med 2004: 350: 786-799.
• Staskin DR, Wein AJ, Andersson KE, et al. Overview
• consensus statement. Urology 2003: 61: 1128-8.
• Alloussi S, Laval KU, Eckert R, et al. Trospium chloride
• in patients with motor urge symptoms: A double blind,
• randomised, multicentre, placebo controlled study. J
• Drug Asses 1999: 2: 27-39.